Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Blinatumomab is a CD19/CD3-bispecific T-cell receptor-engaging (BiTE) antibody with efficacy in refractory B-precursor acute lymphoblastic leukemia. Some patients treated with blinatumomab and other T cell-activating therapies develop cytokine release syndrome (CRS). We hypothesized that patients wi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Teachey, David T., Rheingold, Susan R., Maude, Shannon L., Zugmaier, Gerhard, Barrett, David M., Seif, Alix E., Nichols, Kim E., Suppa, Erica K., Kalos, Michael, Berg, Robert A., Fitzgerald, Julie C., Aplenc, Richard, Gore, Lia, Grupp, Stephan A.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2013
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123427/
https://ncbi.nlm.nih.gov/pubmed/23678006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-02-485623
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares